Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 4
2010 5
2011 5
2012 5
2013 3
2014 3
2015 2
2016 3
2019 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Evolution of raltegravir resistance during therapy.
Sichtig N, Sierra S, Kaiser R, Däumer M, Reuter S, Schülter E, Altmann A, Fätkenheuer G, Dittmer U, Pfister H, Esser S. Sichtig N, et al. Among authors: schulter e. J Antimicrob Chemother. 2009 Jul;64(1):25-32. doi: 10.1093/jac/dkp153. Epub 2009 May 14. J Antimicrob Chemother. 2009. PMID: 19447792
Proviral DNA as a Target for HIV-1 Resistance Analysis.
Lübke N, Di Cristanziano V, Sierra S, Knops E, Schülter E, Jensen B, Oette M, Lengauer T, Kaiser R. Lübke N, et al. Among authors: schulter e. Intervirology. 2015;58(3):184-9. doi: 10.1159/000431093. Epub 2015 Jun 27. Intervirology. 2015. PMID: 26139571
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.
De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A, Codoñer FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration in Chain. De Luca A, et al. J Infect Dis. 2013 Apr 15;207(8):1216-20. doi: 10.1093/infdis/jit017. Epub 2013 Jan 11. J Infect Dis. 2013. PMID: 23315324
Selecting anti-HIV therapies based on a variety of genomic and clinical factors.
Rosen-Zvi M, Altmann A, Prosperi M, Aharoni E, Neuvirth H, Sönnerborg A, Schülter E, Struck D, Peres Y, Incardona F, Kaiser R, Zazzi M, Lengauer T. Rosen-Zvi M, et al. Among authors: schulter e. Bioinformatics. 2008 Jul 1;24(13):i399-406. doi: 10.1093/bioinformatics/btn141. Bioinformatics. 2008. PMID: 18586740 Free PMC article.
HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.
Theys K, Vercauteren J, Snoeck J, Zazzi M, Camacho RJ, Torti C, Schülter E, Clotet B, Sönnerborg A, De Luca A, Grossman Z, Struck D, Vandamme AM, Abecasis AB. Theys K, et al. Among authors: schulter e. Antimicrob Agents Chemother. 2013 Feb;57(2):1053-6. doi: 10.1128/AAC.01668-12. Epub 2012 Nov 26. Antimicrob Agents Chemother. 2013. PMID: 23183438 Free PMC article.
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.
De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, Günthard HF, Wittkop L, Kordossis T, Garcia F, Castagna A, Cozzi-Lepri A, Churchill D, De Wit S, Brockmeyer NH, Imaz A, Mussini C, Obel N, Perno CF, Roca B, Reiss P, Schülter E, Torti C, van Sighem A, Zangerle R, Descamps D; CHAIN and COHERE in EuroCoord. De Luca A, et al. Among authors: schulter e. J Antimicrob Chemother. 2016 May;71(5):1352-60. doi: 10.1093/jac/dkv465. Epub 2016 Jan 28. J Antimicrob Chemother. 2016. PMID: 26825119 Free PMC article.
29 results